Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
3 stories
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Lindahl steps down as principal financial officer December 31, 2026, advises through March 31, 2027, as Vargo takes over January 1, 2027.
SEC filing
In a September 14 investor presentation, the company lowered its 2026 financial outlook and set third-quarter revenue guidance of $110 million to $130 million.
SEC filing